Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy

Data presented during the 2021 American Society of Hematology Annual Meeting demonstrated that induction therapy with twice weekly rusfertide administration was effective in rapidly achieving target hematocrit below 45% without phlebotomy in all polycythemia vera patients with elevated hematocrit and was maintained with weekly rusfertide treatment. The mean rate of absolute hematocrit decrease was 1.76% per week (median: 1.81%/week; min-max: 0.65%-2.69%), and mean time to reach goal hematocrit below 45% was 4.79 weeks (median: 4.14 weeks, min-max: 3.57-8.14).